// App-Quantinova.ai

15849 : Early Increases in Biomarkers Predict Subsequent Cardiotoxicity in Breast Cancer Patients Treated With Doxorubicin, Taxanes, and Trastuzumab

Researchers

Presenter

  • Bonnie Ky

Principal Investigators

  • Heloisa Sawaya

  • Randolph P Martin

  • Michael Picard

  • Robert Gerstzen

  • Elkan Halpern

  • Jonathan Passeri

  • Kuter Irene

  • Marielle Scherrer-Crosbie

  • Benjamin French

  • James L Januzzi

  • Igal Sebag

  • Juan Planas

  • Victor Cohen

  • Jose Blanchs

  • Joseph Carver

  • Susan Wiegers

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • PRA Intl, Raleigh, NC

  • University of Pennsylvania, Philadelphia, PA

  • Sir Mortimer B Davis-Jewish General Hosp and McGill Univ, Montreal, QC

  • Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada

  • Piedmont Health: Heart Inst, Atlanta, GA

  • 1.MD Anderson Cancer Center, Houston, TX

  • Cleveland Clinic Foundation, Cleveland, OH

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Drexel University, Philadelphia, PA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cardiotoxicity

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Myeloperoxidase

  • C reactive protein

  • Fms related tyrosine kinase 1

  • Growth differentiation factor 15

  • High sensitivity C-reactive protein

  • Human epidermal growth factor receptor 2

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Trastuzumab

  • Doxorubicin

  • L-Tyrosine

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved